CA225103: A phase II study of a combination of cetuximab and capecitabine in patients with metastatic colorectal cancer after progression on previous fluoropyrimidine containing therapy.

Trial Profile

CA225103: A phase II study of a combination of cetuximab and capecitabine in patients with metastatic colorectal cancer after progression on previous fluoropyrimidine containing therapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Jul 2016

At a glance

  • Drugs Capecitabine (Primary) ; Cetuximab (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Dec 2009 Actual end date (Feb 2009) added as reported by ClinicalTrials.gov.
    • 01 Jan 2008 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top